1-3 of 3
Erica Fong
Close
Sort by
Journal Articles

Efficacy and Safety of 1500 mg Voxelotor in a Phase 2a Study (GBT440-007) in Adolescents with Sickle Cell Disease

Clark Brown, Carolyn Hoppe, Adlette Inati, Miguel R. Abboud, Winfred Wang, MD, Robert Liem, MD, Gerald Woods, Lewis L. Hsu, Victor R. Gordeuk, MD, Connie Piccone, Richard A. Drachtman, Erica Fong, Sandra Dixon, Margaret Tonda, PharmD, Carla Washington, Joshua Lehrer-Graiwer
Journal: Blood
Blood (2018) 132 (Supplement 1): 509.
https://doi.org/10.1182/blood-2018-99-117510
Published: 2018
Journal Articles

The Pharmacokinetics (PK) of GBT440 Following Single Doses in Pediatric Patients with Sickle Cell Disease (SCD)

Carla B Washington, PhD, Michelle Green, PhD, Adlette C. Inati, MD, Clark Brown, MD PhD, Carolyn C Hoppe, MD, Winfred Wang, MD, Ganesh Balaratnam, MD, Sandra Dixon, MS, Erica Fong, Athiwat Hutchaleelaha, PhD, Margaret E Tonda, PharmD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 980.
https://doi.org/10.1182/blood.V130.Suppl_1.980.980
Published: 2017
Journal Articles

Initial Results from a Cohort in a Phase 2a Study (GBT440-007) Evaluating Adolescents with Sickle Cell Disease Treated with Multiple Doses of GBT440, a HbS Polymerization Inhibitor

Carolyn C Hoppe, MD, Adlette C. Inati, MD, Clark Brown, MD PhD, Winfred Wang, MD, Victor R. Gordeuk, MD, Robert Liem, MD, Gerald Woods, MD, Connie M. Piccone, MD, Erica Fong, Ganesh Balaratnam, MD, Sandy Dixon, Margaret E Tonda, PharmD, Carla B Washington, PhD, Yifah Yaron, MD PhD, Josh Lehrer, MD MPhil, FACC
Journal: Blood
Blood (2017) 130 (Supplement 1): 689.
https://doi.org/10.1182/blood.V130.Suppl_1.689.689
Published: 2017